Quantitation and modeling of quality attributes of therapeutic monoclonal antibodies
US11355217B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 31, 2019 |
| Grant date | Jun 7, 2022 |
| Priority date | — |
| Expiry date | Sep 16, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16B20/20
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Methods of predicting an in vivo serum concentration of an antibody with a post-translational modification of interest after administration of the antibody are provided, as are methods for predicting a subject's exposure to post-translational variants of the antibody. The methods include predicting a percentage of the antibody with the post-translational modification of interest using an in vivo rate constant determined for the post-translational modification, and multiplying the predicted percentage of the antibody with the post-translational modification of interest by the in vivo concentration of the antibody to determine the concentration of the antibody with the post-translational modification of interest.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.